Abbott Laboratories vs ABRDN Physical Gold Shares ETF — how do they compare? Abbott Laboratories trades at $109.6 (market cap $187.95B), while ABRDN Physical Gold Shares ETF trades at $42.19. The key difference: Abbott Laboratories pays a 2.32% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals.
| ABT | SGOL | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $136.62 | $51.41 |
52-Week Low | $82.57 | $31.61 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
SGOL trades at $42.21, up 0.98% with a bullish technical signal from moving averages, though oscillators show caution with RSI at overbought levels. The gold ETF benefits from recent CPI data showing cooling inflation and strong central bank demand, with spot gold prices testing key resistance levels. Financial ratios remain unavailable for this commodity-focused ETF structure.
The outlook remains positive given gold's momentum and macroeconomic support, though overbought conditions suggest potential near-term consolidation. Key risks include Fed policy shifts and dollar strength, while institutional buying provides underlying support for the gold thesis.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →